Blue Lake Biotechnology, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Study of BLB-201 RSV Vaccine in Infants and Children
Phase 1
Recruiting
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: PIV5-vectored RSV Vaccine (BLB-201) Low DoseDrug: PlaceboBiological: PIV5-vectored RSV Vaccine (BLB-201) High Dose
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Blue Lake Biotechnology Inc.
- Target Recruit Count
- 137
- Registration Number
- NCT05655182
- Locations
- 🇺🇸
Paradigm Clinical Research, La Mesa, California, United States
🇺🇸Velocity Clinical Research, Boise, Meridian, Idaho, United States
🇺🇸Clinical Research Prime, Rexburg, Idaho, United States
Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Blue Lake Biotechnology Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05281263
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Coastal Carolina Research Center, North Charleston, South Carolina, United States
News
No news found